Intellia Therapeutics (NTLA) Operating Expenses (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Operating Expenses of $115.6 million for Q1 2026, down 15.9% year-over-year from $137.4 million in Q1 2025, and down 5.05% quarter-over-quarter from $121.7 million in Q4 2025.
Intellia Therapeutics (NTLA) Operating Expenses (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Operating Expenses for 12 consecutive years, with $115.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 15.9% year-over-year to $115.6 million; the TTM figure through Mar 2026 stood at $486.8 million (down 17.02% YoY), while the FY2025 annual figure was $508.7 million, down 14.1% from the prior year.
- Operating Expenses fell to $115.6 million in Q1 2026 per NTLA's latest filing, from $121.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $155.5 million in Q1 2022 and bottomed at $112.3 million in Q2 2022.
- Historically, Operating Expenses has averaged $134.0 million across 5 years, with a median of $137.4 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 194.11% — and 2023, when it dropped 19.89%.
- Intellia Therapeutics' Operating Expenses stood at $123.7 million in 2022, then advanced by 11.58% to $138.0 million in 2023, then increased by 8.22% to $149.3 million in 2024, then retreated by 18.48% to $121.7 million in 2025, then retreated by 5.05% to $115.6 million in 2026.
- Business Quant data shows NTLA's Operating Expenses at $115.6 million in Q1 2026, $121.7 million in Q4 2025, and $125.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 120.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.42 Mn |
| Mar 31, 2026 | 115.58 Mn |
| Dec 31, 2025 | 121.73 Mn |
| Sep 30, 2025 | 125.26 Mn |
| Jun 30, 2025 | 124.24 Mn |
| Mar 31, 2025 | 137.43 Mn |
| Dec 31, 2024 | 149.32 Mn |
| Sep 30, 2024 | 153.88 Mn |
| Jun 30, 2024 | 146.00 Mn |
| Mar 31, 2024 | 142.94 Mn |
| Dec 31, 2023 | 137.98 Mn |
| Sep 30, 2023 | 143.10 Mn |
| Jun 30, 2023 | 145.93 Mn |
| Mar 31, 2023 | 124.56 Mn |
| Dec 31, 2022 | 123.66 Mn |
| Sep 30, 2022 | 118.80 Mn |
| Jun 30, 2022 | 112.33 Mn |
| Mar 31, 2022 | 155.50 Mn |
| Dec 31, 2021 | 93.27 Mn |
| Sep 30, 2021 | 79.20 Mn |